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194 Clinical impact of inhaled mannitol in an adult cystic ﬁbrosis
population
B.M. Button1,2, F. Finlayson1, B. Borg1, S. Ivulich3, J.W. Wilson1,2. 1Alfred
Hospital, AIRmed, Melbourne, Australia; 2Monash University, Medicine,
Melbourne, Australia; 3Alfred Hospital, Pharmacy, Melbourne, Australia
Inhaled mannitol (IM) was approved for use in Australia in August 2012.
Objectives: to evaluate the clinical impact of IM in suitable patients.
Methods: Patients’ responses to the Initiation Dose (ID) of 400mg of IM powder
via a small inhaler device were evaluated to exclude hyperresponsiveness using the
lung function database. Concurrent use of Dornase Alpha (DA) & hypertonic saline
(HS) using the hospital pharmacy dispensing database and breathing technique were
evaluated.
Results: Twenty-six adults (15 women) 35.4 years (7.8, 21−50) − mean (SD, range)
were referred for the Initiation Dose. Baseline FEV1 2.19 (1.15, 0.79–5.04) after-
bronchodilator FEV1 2.25 (1.16) and post IM ID FEV1 2.06 (1.19) L. The post
IM ID change was −9.23 (10.2, −27 to +7)%. Eight patients had no drop or an
increase in FEV1, six patients did not qualify for use of IM with >20% drop in
FEV1. Twenty patients have continued to use IM as a mucolytic agent adjunctive
to airway clearance therapy, 8 use IM and DA on a daily basis; 11 use IM and
HS, and 5 use IM and DA and HS. The correct breathing technique (slow and
deep inspiration with an inspiratory ﬂow of around 30 L per minute) is crucial in
preventing unnecessary coughing & bronchospasm. Patients report the beneﬁts of
IM being easy to use, no equipment cleaning, effective and time efﬁcient (5 minutes
for inhalation of 10 capsules am and pm). Four patients report a transient feeling
of chest tightness after using IM. IM has not been available for long enough to
evaluate longer term lung function outcomes.
Conclusion: IM has been enthusiastically welcomed by patients with CF as a stand
alone mucolytic agent or in combination with DA and or HS.
195 Efﬁcacy of inhaled amiloride solution versus hypertonic saline,
prospective open label single center study in children with cystic
ﬁbrosis
L. Homola1,2,3, A. Holcˇı´kova´1,2,3, P. Mikola´sˇek1,2, L. Krbkova´1,2. 1Faculty
Hospital Brno, Child Infectious Diseases Clinic, Brno, Czech Republic; 2Masaryk
University, Brno, Czech Republic; 3CF Centre South Moravia, Brno, Czech
Republic
Objectives: The aim of the study was to compare efﬁcacy of inhaled amiloride
solution against standard therapy of hypertonic saline in children with CF.
Methods: Prospective open label single center study. Group of 45 children with
CF from our centre were randomised in 1:2 ratio. 30 children were assigned to
amiloride (A) arm and 15 children in 5% hypertonic saline (HS) control arm.
Amiloride was prepared in water solution of amiloride chlorate. The dose was
0.6mg twice daily administered via pari boy. Both groups were similar in mean
age, sex, CFTR mutations, sweat chloride, pancreatic insuﬁciency, rDNAse, and
chronic P. aeruginosa infection. Patients were observed in week 0, 12, 24 and 36.
The differences in FEV1, exacerbations (modiﬁed Fuchs et al.), sputum cultivations,
growth, weight, lung CT, hospital admission and drug tolerance were evaluated.
Results: Groups did not differ signiﬁcantly in change of FEV1 (A +0.36%;
HS −3.5%), number of exacerbations (A 1.6±1.4; HS 1.4±1.2), weeks to 1st ex-
acerbation (A 20±13; HS 26±11), progression in lung CT (A 30%; HS 36%)
number of positive sputum cultivations per patient (A 4.1; HS 3.8) rate of new
P. aeruginosa cultivation (A 16%; HS 13%), weight gain (A +1.6 kg; HS +1.2 kg),
growth (A +3.2 cm; HS +2.5 cm).
Signiﬁcant difference was found in rate of hospital admission (A 13%; HS 33%,
p = 0.09), in drug tolerance (A 100%; HS 80%, p = 0.04).
Conclusion: Inhaled amiloride solution was found less irritating and led to less
hospital admissions then hypertonic saline, the other differences were not signiﬁ-
cant.
Further crossover study follows in 2014 to add more power to results.
Study was funded by Masaryk University grant MUNI/A/0861/2011.
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Objectives: Deposition of inhaled antibiotics (IA) is higher in well preserved
lung areas compared to obstructed airway regions. This may result in areas with
concentration below minimal inhibitory concentration (MIC) causing under-treated
lung parts. A computational model may be used to gain knowledge about antibiotic
concentrations throughout the lung, possibly resulting in optimization of inhaled
therapy. We aim to develop a patient-speciﬁc assessment tool, using computational
ﬂuid dynamics (CFD), that provides local depositions and concentrations of aztre-
onam lysine for inhalation (AZLI).
Methods: In- and expiratory CT-scans of children with CF (5−18 yr) are scored
(CF-CT score), segmented and reconstructed into 3D airway models. We performed
CFD simulations, using patient-speciﬁc lobar ﬂow distribution, nebulisation of
75mg AZLI through PARI eFlow® with reported MMAD range and thickness
range of Airway Surface Liquid (ASL). Percentage of total airway area with AZLI
concentration <10×MIC90 (1280mg/ml) for P. aeruginosa are computed.
Results: 40 CT-scan sets from 31 patients (65% female) were selected, median
[range] age 10.5 [5−17] years, bronchiectasis score 4.3 [0.0–26.7] % of max. CF-CT
score, FEV1 91.5 [69.4–113.4] %pred. Preliminary results of 19 patients (Table 1)
show % of under-dosed areas. Simulations are on-going. We will study associations
with age and disease severity, which will be reported at the conference.
Conclusion: Considerable parts of the CF-lung can receive IA concentrations
<10×MIC90, depending on disease severity.
Funding: Gilead Sciences.
MMAD and ASL values vs % under-dosed area
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197 Inﬂuence of inhalation mode on aerosol lung deposition in
patients with cystic ﬁbrosis PART 1: Pharmacokinetic data as
representative of lung deposition
A.J. van Velzen1, P. Shahbabai1, J.W.F. Uges1, D.J. Touw1, H.G.M. Heijerman2.
1Central Hospital Pharmacy, The Hague, Netherlands; 2Haga Teaching Hospital,
Pulmonology, The Hague, Netherlands
Objectives: To investigate the impact of two different inhalation ﬂow maneuvers
(TIM = slow and deep inhalation and TBM = normal tidal breathing) on aerosol lung
deposition in patients with CF using pharmacokinetic parameters as a representation
of lung deposition.
Methods: Randomized, open-label, cross-over study. The study group consisted of
18 adult patients with a conﬁrmed diagnosis of CF (genetic analysis). Each patient
inhaled a tobramycin solution twice during separate study visits: once in TIM and
the other time in TBM mode. Blood samples were collected in order to model
tobramycin pharmacokinetics.
Outcome measurements: Relative bioavailability (Frel) of tobramycin is deﬁned
as the ratio of AUCTIM to AUCTBM, in which the AUC represents the plasma
concentration area under the curves. A ratio greater than 1 indicates higher lung
deposition for TIM compared to TBM. Individual pharmacokinetic parameters
were calculated and assimilated with patient tobramycin serum values using a
computerized CF-based Bayesian population model (MW-Pharm, Mediware).
Results: Frel was 1 or greater for all patients (mean = 1.55, sd = 0.39, 95%CI =
1.37–1.73). In addition, mean Frel was signiﬁcant higher than the value of 1 (mean
difference = 0.55, p< 0.001, 95%CI = 0.36–0.74). Mean maximum serum levels
(Cmax) were also signiﬁcantly increased for TIM compared to TBM. Differences
in elimination half-life and time to maximum serum level were not statistically
signiﬁcant.
Conclusion: Slow and deep inhalation of aerosolized tobramycin results in higher
lung deposition compared to normal tidal breathing, represented by a relative
bioavailability greater than 1 and increased mean maximum serum levels.
